117 results on '"Cañete N"'
Search Results
2. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors
3. Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding
4. Multidisciplinary Support Program for patients with addictions and suspected chronic hepatitis C (MSPADIC-C) to improve their evaluation and access to antiviral treatment
5. Body mass index influences Controlled Attenuation Parameter (CAP) values measured with Fibroscan ® M probe. When should we evaluate steatosis with the XL probe?
6. Impact of sustained virological response in the use of concomitant drugs in hepatitis C virus infected patients with comorbidities
7. Use of rifaximin in alcoholic hepatitis: Pilot study
8. Controlled attenuation parameter values of Fibroscan ® compatible with steatosis in patients with chronic hepatitis C and changes after sustained virological response
9. Effect of silibinin nutraceutical supplementation in brain metastases of patients with advanced lung cancer
10. Survival in patients with chronic hepatitis C and mild-moderate fibrosis according to antiviral treatment response
11. Predictive model of mortality in patients with spontaneous bacterial peritonitis
12. Non-Invasive Assessment of Steatosis and Liver Fibrosis in Overweight and Obese Patients
13. Non-Invasive Evaluation of Chronic Hepatitis C Patients with Moderate Fibrosis (F2) Long-Term Impact of Antiviral Treatment
14. Enhanced Liver Fibrosis (ELF) Test Quantification in HBeAg-Negative Patients with Nucleos(T)Ide Analogues 1, 3, 5 and 8 Years after Liver Biopsy
15. Quantification of HBsAg (HBsAg-Q) in HBeAg-Negative Patients Receiving Nucleos(T)ide Analogues to Predict the Loss of HBsAg
16. SAT-466 - Use of rifaximin in alcoholic hepatitis: Pilot study
17. FRI-474 - Body mass index influences Controlled Attenuation Parameter (CAP) values measured with Fibroscan® M probe. When should we evaluate steatosis with the XL probe?
18. FRI-412 - Impact of sustained virological response in the use of concomitant drugs in hepatitis C virus infected patients with comorbidities
19. FRI-404 - Controlled attenuation parameter values of Fibroscan® compatible with steatosis in patients with chronic hepatitis C and changes after sustained virological response
20. THU-316 - Multidisciplinary Support Program for patients with addictions and suspected chronic hepatitis C (MSPADIC-C) to improve their evaluation and access to antiviral treatment
21. Clinical Value of Thyrotropin Receptor Antibodies for the Differential Diagnosis of Interferon Induced Thyroiditis
22. P0190 : Predictive model of mortality in cirrhotic patients with high risk spontaneous bacterial peritonitis
23. P0515 : Biological stability and diagnostic accuracy of ELF® (enhanced liver fibrosis test) to identify liver fibrosis in patients with chronic hepatitis C using cryopreserved serum samples during 25 years
24. P0846 : Evaluation of adherence to telaprevir (TVR) and boceprevir (BOC) using different thresholds
25. Neutrophil function in patients with chronic hepatitis C (CHC) undergoing triple antiviral therapy (TT) with first and second generation protease inhibitors (PI)
26. Small bowel perforation by an unusual foreign body
27. 361P - Effect of silibinin nutraceutical supplementation in brain metastases of patients with advanced lung cancer
28. Applicability and accuracy improvement of transient elastography using the M and XL probes by experienced operators
29. SAT-454 - Non-Invasive Evaluation of Chronic Hepatitis C Patients with Moderate Fibrosis (F2) Long-Term Impact of Antiviral Treatment
30. SAT-462 - Enhanced Liver Fibrosis (ELF) Test Quantification in HBeAg-Negative Patients with Nucleos(T)Ide Analogues 1, 3, 5 and 8 Years after Liver Biopsy
31. FRI-341 - Non-Invasive Assessment of Steatosis and Liver Fibrosis in Overweight and Obese Patients
32. THU-164 - Quantification of HBsAg (HBsAg-Q) in HBeAg-Negative Patients Receiving Nucleos(T)ide Analogues to Predict the Loss of HBsAg
33. 801 LONG-TERM EVOLUTION OF LIVER FIBROSIS IN MILD–MODERATE CHRONIC HEPATITIS C: STUDY WITH PAIRED BIOPSIES
34. 729 VARIABLES RELATED TO INADEQUATE LIVER STIFFNESS MEASUREMENTS USING TRANSIENT ELASTOGRAPHY. ANALYSIS OF 895 EXAMINATIONS
35. 713 IMPROVEMENT OF TRANSIENT ELASTOGRAPHY APPLICABILITY TO EVALUATE LIVER STIFFNESS BY TRAINED OPERATORS AND USING XL PROBE
36. Clinical Value of Thyrotropin Receptor Antibodies for the Differential Diagnosis of Interferon Induced Thyroiditis.
37. Long-Term Follow-Up of 1,000 Patients Cured of Helicobacter pylori Infection Following an Episode of Peptic Ulcer Bleeding
38. PIN62 A Multidisciplinary Support program in Hepatitis C Treatment: An Economic Evaluation
39. Eradication of Helicobacter pylori for the Prevention of Peptic Ulcer Rebleeding. Long-Term Follow-up Study of 890 Patients
40. 326 A NEW NON INVASIVE INDEX (MAR-C) TO IDENTIFY SIGNIFICANT FIBROSIS IN CHRONIC HEPATITIS C. A COHORT OF 1088 PATIENTS
41. 461 ACUTE HEPATITIS C IN SPAIN. RETROSPECTIVE STUDY OF 131 PATIENTS
42. M1112 Eradication of Helicobacter pylori for the Prevention of Peptic Ulcer Rebleeding. Long-Term Follow-up Study of 800 Patients
43. Small bowel perforation by an unusual foreign body
44. Casos en Imagen: 1.—Receso pericárdico de la vena pulmonar inferior derecha (pericardial « sleeve» recess) simulando una adenopatía mediastínica
45. Eradication ofHelicobacter pylorifor the prevention of peptic ulcer rebleeding
46. Su1722a Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding: Long-term follow-up study of 1,000 patients
47. Acute hepatitis C in Spain: a retrospective study of 131 cases
48. Recurrent alcohol-associated hepatitis is common and is associated with increased mortality.
49. Epicardial Space: Comprehensive Anatomy and Spectrum of Disease.
50. Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.